A new review from Beijing Chest Hospital, Capital Medical University, systematically expounds the dual role of DNA repair core protein Rad51 in tumors. This article reveals that Rad51 not only maintains genomic stability through homologous recombination repair, but its overexpression is also closely related to chemotherapy, radiotherapy and PARP inhibitor resistance in various cancers. Most importantly, the review delves deeply into how Rad51 shapes the tumor immune microenvironment by regulating the cGAS-STING pathway, influencing neoantigen generation and PD-L1 expression, providing a new theoretical basis for the anti-cancer strategy of combining Rad51 with immune checkpoint inhibitors.

In a new study, coauthors Jordan Yaron, Kaushal Rege and their colleagues with the Biodesign Center for Biomaterials Innovation and Translation discovered that the protein SerpinB3 is part of the body’s natural wound-healing arsenal, helping the skin recover after damage. 

The research points to new possibilities: Boosting it could improve wound healing, while blocking it may offer a way to fight aggressive cancers. The findings may also help explain SerpinB3’s role in inflammatory ailments, from skin conditions to asthma.

The University of Cincinnati Cancer Center’s Trisha Wise-Draper, MD, PhD, will present early data from a Phase 2 clinical trial showing a combination of immunotherapy medications can activate a robust immune response and help overcome treatment resistance in patients with refractory melanoma at the Society for Immunotherapy of Cancer 40th Anniversary Annual Meeting Nov. 7.